These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18612528)

  • 1. Beyond glucose levels in diabetic patients with coronary artery disease: platelet activity and non-responsiveness to antiplatelet therapy.
    Shantsila E; Lip GY
    Thromb Haemost; 2008 Jul; 100(1):7-8. PubMed ID: 18612528
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
    Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.
    Mortensen SB; Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Res; 2010 Oct; 126(4):e318-22. PubMed ID: 20451957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelets and antiplatelet therapy in patients with diabetes mellitus.
    Arjomand H; Roukoz B; Surabhi SK; Cohen M
    J Invasive Cardiol; 2003 May; 15(5):264-9. PubMed ID: 12730635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
    Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
    Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic examination before clinical examination. That is why it is worthwhile to return to the laboratory].
    Kuliczkowski W
    Kardiol Pol; 2009 Jun; 67(6):599-600. PubMed ID: 19852089
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches.
    Badimon L; Badimon JJ; Fuster V
    Z Kardiol; 1990; 79 Suppl 3():133-45. PubMed ID: 2099036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D; Varenhorst C; Braun OO; James S; Winters KJ; Jakubowski JA; Brandt JT; Sugidachi A; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2008 Dec; 52(24):1968-77. PubMed ID: 19055987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor aspirin response in diabetic patients presenting with acute coronary syndromes: results using a near patient test.
    Amoah V; Smallwood A; Worrall AP; Lovatt T; Armesilla AL; Nevill AM; Cotton JM
    Thromb Res; 2011 Aug; 128(2):196-9. PubMed ID: 21543109
    [No Abstract]   [Full Text] [Related]  

  • 13. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
    Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
    Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
    J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
    Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
    Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
    Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
    Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy.
    Mende A; Obata JE; Sano K; Hirano M; Kitta Y; Kodama Y; Nakamura T; Kawabata K; Saitoh Y; Fujioka D; Kobayashi T; Satoh K; Ozaki Y; Yano T; Kugiyama K
    Thromb Res; 2009 Apr; 123(6):856-61. PubMed ID: 19004478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of calpain in diabetes-associated platelet hyperactivation.
    Randriamboavonjy V; Fleming I
    Adv Pharmacol; 2010; 59():235-57. PubMed ID: 20933204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
    Wiviott SD; Flather MD; O'Donoghue ML; Goto S; Fitzgerald DJ; Cura F; Aylward P; Guetta V; Dudek D; Contant CF; Angiolillo DJ; Bhatt DL;
    Circulation; 2011 May; 123(17):1854-63. PubMed ID: 21502571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.